Vitamin D3 for Life

Live Enlightened

Article

Roles of CYP27B1 and CYP24A1 in activation and inactivation: Study Summary

Previous related pageRoles of CYP27B1 and CYP24A1 in activation and inactivation: Full Study SummaryNext related pageSkin Vitamin D Synthesis, Local Activation and Signalling: Full Evidence Review
Study at a glance

Which enzymes help make and remove active vitamin D?

This page summarises evidence about two enzymes, proteins that help chemical reactions occur. CYP27B1 helps make active vitamin D, while CYP24A1 helps process forms of vitamin D for removal. The review brings together laboratory experiments, genetically modified mice, human genetic disorders and hormone studies. These are different sources of evidence, not one study population.

How do these enzymes control the supply of active vitamin D?

CYP27B1 changes 25-hydroxyvitamin D into calcitriol, the main active vitamin D hormone. CYP24A1 processes both the earlier form and calcitriol through several steps, limiting how much remains available and for how long. Hormones coordinate these processes in the kidneys. Parathyroid hormone usually favours production, while FGF23 and calcitriol itself favour less active vitamin D being available.

What happened when vitamin D-processing enzymes were changed or missing?

Changes to the structure of CYP24A1 changed which products it made in laboratory tests. In mice completely lacking this enzyme, the time for blood calcitriol to fall by half increased from about 6 to 60 hours. Human genetic disorders also show the importance of these enzymes: severe failure of activation or removal can disturb calcium control. The mouse timing result is not an estimate for ordinary human differences.

Does vitamin D processing always make it inactive straight away?

Finding an activating enzyme outside the kidneys does not prove that the tissue supplies much active vitamin D to the blood. CYP24A1 is a major processing route, but other enzymes can contribute. Processing also occurs in stages, and not every substance made along the way becomes inactive straight away. Results from different species and methods must keep their separate limits.

Read the full article below ↓

CYP27B1 and CYP24A1 control opposite sides of active vitamin D metabolism. The review by Jones, Prosser and Kaufmann brings together biochemical, structural, genetic and physiological evidence showing how CYP27B1 forms calcitriol from 25-hydroxyvitamin D, while CYP24A1 progressively metabolises both precursor and active hormone. The key idea is not simply “activation versus destruction,” but a regulated balance between formation, local use, feedback and clearance.

What question does the review help answer?

The review examines the cytochrome P450 enzymes involved in vitamin D metabolism, within the broader Vitamin D Enzyme Pathways (CYP27B1 / CYP24A1) framework. For the CYP27B1/CYP24A1 pathway, it explains which enzyme performs the decisive 1α-hydroxylation step, how CYP24A1 routes vitamin D metabolites through C24: and C23-initiated pathways, how enzyme structure changes product distribution, and how genetics and endocrine feedback reveal the physiological importance of those reactions.

Because it is a review rather than a single experiment, its evidence comes from multiple models and methods. Recombinant-enzyme studies establish catalytic capacity; mutagenesis links protein structure to product choice; knockout mice test physiological necessity; human mutations reveal disease consequences; and endocrine studies show how the kidney adjusts activation and catabolism in opposite directions.

How does CYP27B1 activate vitamin D?

CYP27B1 is the established 25-hydroxyvitamin D 1α-hydroxylase. It converts 25(OH)D to 1,25(OH)2D, or calcitriol, the high-affinity hormonal ligand for VDR. Human CYP27B1 loss-of-function causes vitamin-D-dependent rickets type 1A, showing that adequate precursor cannot compensate for severe failure of the activation step.

CYP27B1 is a mitochondrial P450 enzyme. Its reaction depends on mitochondrial electron transfer through redox partners as well as on substrate availability. The kidney is the principal regulated source of circulating calcitriol, while extra-renal CYP27B1 commonly supports more local intracrine or paracrine signalling.

How does CYP24A1 reduce vitamin D exposure?

CYP24A1 can metabolise both 25(OH)D and calcitriol. It can therefore reduce substrate available for later activation and shorten active-hormone exposure after calcitriol has formed.

The enzyme is not limited to one 24-hydroxylation step. It can initiate C24 and C23 oxidation routes and then perform further side-chain oxidations. These pathways lead toward different downstream metabolites, including calcitroic-acid and lactone-related products. This is progressive catabolism rather than an instantaneous molecular off switch.

What do structure and genetics add to the picture?

Active-site mutagenesis shows that CYP24A1 product routing depends on substrate orientation inside the enzyme. Wild-type rat CYP24A1 showed a C24:C23 ratio of roughly 100:1 in a cited series. Individual substitutions shifted that ratio to about 12.5:1 and 6.3:1, compared with about 3.7:1 for human CYP24A1. Small structural changes can therefore redirect metabolic flux substantially.

The physiological effect of CYP24A1 loss is equally striking. In Cyp24a1-null mice, calcitriol plasma half-life increased from roughly 6 hours to roughly 60 hours. Human loss-of-function variants are also associated with idiopathic infantile hypercalcaemia and related hypercalcaemic phenotypes. Together, these findings show that CYP24A1 is a major determinant of vitamin D metabolite persistence.

How are activation and catabolism coordinated?

Renal regulation moves CYP27B1 and CYP24A1 in reciprocal directions. PTH generally favours calcitriol production; FGF23 favours lower active-hormone availability; and calcitriol feeds back by suppressing CYP27B1 while strongly inducing CYP24A1. Production and removal therefore respond together rather than behaving as independent reactions.

CYP24A1 remains the specialised central catabolic enzyme, but it is not literally the only oxidative route in every tissue. CYP3A4 can also metabolise vitamin D compounds, especially in liver, intestine and inducible exposure settings.

What should not be concluded from this evidence?

The quantitative results come from different experimental systems, so rat product ratios, mouse knockout half-lives and human disease phenotypes should not be treated as if they were measurements from one study population. Extra-renal expression does not prove a major contribution to circulating calcitriol, complete gene knockout does not predict the effect size of ordinary variation, and the existence of some biologically active downstream metabolites does not overturn CYP24A1’s dominant catabolic role.

The most secure conclusion is that CYP27B1 creates the principal active vitamin D hormone and CYP24A1 is central to limiting precursor and active-hormone exposure through regulated multistep metabolism.

Primary source and further reading

Jones G, Prosser DE, Kaufmann M. Cytochrome P450-mediated metabolism of vitamin D. Journal of Lipid Research. 2014;55(1):13 to 31. PMID 23564710; PMCID PMC3927478; DOI 10.1194/jlr.R031534.

Read the full Jones, Prosser and Kaufmann paper. For the deeper structural, genetic and physiological treatment, read the Full Evidence Review.

Related reading

Original sources